Meta-Analysis:
Long noncoding RNA AFAP1AS1 is a novel biomarker in various cancers: a systematic review and metaanalysis based on the literature and GEO datasets
PDF | Full Text | How to cite
Metrics: PDF 2709 views | Full Text 3762 views
Yumin Wang1,2,3,*, Yongzhen Mo1,2,3,*, Xiang Yang1, Ruoyu Zhou1,2, Zeyu Wu1, Yuchen He1, Xue Yang1,2, Yaxian Zhong1,2, Yajun Du1,2, Hang Zhou1, Xiaoling Li1,2,3, Yong Li2,4, Guiyuan Li1,2,3, Zhaoyang Zeng1,2,3, Can Guo1,2,3 and Wei Xiong1,2,3
1Key Laboratory of Carcinogenesis of Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan, China
2Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China
3Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China
4Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
*These authors contributed equally to this work
Correspondence to:
Wei Xiong, email: [email protected]
Can Guo, email: [email protected]
Keywords: long noncoding RNA, cancer, AFAP1-AS1, meta-analysis, biomarker
Received: August 06, 2017 Accepted: September 23, 2017 Published: October 11, 2017
ABSTRACT
Background Growing evidence indicates that AFAP1-AS1 plays an important role in various cancers, suggesting that it might be a potential cancer biomarker.
Materials and Methods: A meta-analysis was performed using microarray data obtained via the Affymetrix Human Genome U133 Plus 2.0 platform (found in the GEO database) and data obtained through a systematic search of PubMed and Web of Science. The pooled odds ratio (OR) and hazard ratio (HR) with 95% CI (confidence interval) were used to judge the value of biomarkers.
Results: A total of 30 studies were included in this meta-analysis, comprising a total of 3573 patients. AFAP1-AS1 was significantly linked with overall survival (OS) (HR = 1.58; 95% CI: 1.12–2.23) and recurrence-free survival (RFS) (HR = 2.32, 95% CI: 1.68–3.19). We found that AFAP1-AS1 was a risk factor in the prognoses of lung cancer (pooled HR: 1.54; 95% CI: 1.01–2.34), digestive system cancer (pooled HR: 1.87; 95% CI: 1.45–2.41) and nasopharyngeal carcinoma (HR: 11.82; 95% CI: 5.09–27.46). AFAP1-AS1 was also a risk factor for RFS in breast cancer (pooled HR = 2.90; 95% CI: 1.69–4.98), as well as TNM stage in both esophageal cancer (pooled OR = 1.90; 95% CI: 1.01–3.57) and colorectal cancer (OR = 6.72; 95% CI: 1.92–23.58). AFAP1-AS1 was significantly associated with lymph node metastasis in clear cell carcinoma (OR = 5.04; 95% CI: 2.36–10.78) and distant metastasis in pancreatic cancer (OR = 11.64; 95% CI: 2.13–63.78).
Conclusions: AFAP1-AS1 can serve as a novel molecular marker predicting tumor progression, patient prognosis and lymph node metastasis in different types of cancers.